Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market

Jun 17, 2025

0 likes | 1 Vues

The global non small cell lung cancer (NSCLC) therapeutics market size was valued at USD 33.90 billion in 2024. The market is projected to grow from USD 38.49 billion in 2025 to USD 66.04 billion by the end of 2032, exhibiting a CAGR of 10.3% during the forecast period (2024-2032). North America dominated the non small cell lung cancer therapeutics market with a market share of 44.45% in 2024.

Share Presentation

Embed Code

Link

rucha8

Télécharger la présentation

Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Non-small Cell Lung Cancer

Small cell lung cancer: chemotherapy (+radiation for limited stage) ... Decline in California lung cancer rates 1988-1997 declined 14%, compared with ...

1.16k views • 50 slides

IRESSA ® (ZD1839) Monotherapy for Non-Small Cell Lung Cancer (NSCLC)

ONCOLOGY. IRESSA ® (ZD1839) Monotherapy for Non-Small Cell Lung Cancer (NSCLC). Oncologic Drugs Advisory Committee Meeting September 24, 2002. IRESSA ® Introduction. George Blackledge, MD Clinical Vice President, Oncology AstraZeneca Pharmaceuticals. IRESSA ® Agenda for Today’s Meeting.

588 views • 34 slides

Advanced Non-Small Cell Lung Cancer: State of the Art

Advanced Non-Small Cell Lung Cancer: State of the Art. Primo N. Lara, Jr., MD Professor of Medicine University of California Davis Cancer Center. Frontline therapy of advanced NSCLC: “Back in the day” dogma (ie, 2009).

698 views • 49 slides

Old dogmas, new tricks: the changing treatment of advanced non-small cell lung cancer

Faculty Disclosures . Dr Goodgame has received: Consulting fees from Abraxis Bioscience. Honoraria from Lilly Oncology. Old dogmas. Locally advanced NSCLC with pleural dissemination is considered wet" IIIB and is treated as stage IV disease.A platinum doublet is the standard of care for medica

356 views • 23 slides

Non-small Cell Lung Cancer

Non-small Cell Lung Cancer. Eva Szabo, MD Division of Cancer Prevention, NCI. TRACO 11-14-11. US Lung Cancer Statistics, 2010 227,890 estimated new cases. 158,070 estimated deaths leading cause of cancer deaths greater than breast+prostate+colon

2.28k views • 57 slides

Non-small-cell lung cancer

Non-small-cell lung cancer. DR.Mohammed Awad. Incidence. The most common cause of cancer mortality in both sex (1/3 of cancer deaths) About 90% of lung cancer mortality among men (and 80% among women) is attributable to smoking.

595 views • 28 slides

Non-small-cell lung carcinoma

Non-small-cell lung carcinoma. Non-small-cell lung carcinoma ( NSCLC ) is any type of epithelial lung cancer other than small cell lung carcinoma ( SCLC). As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small cell carcinoma.

788 views • 21 slides

Relating Activating K-Ras Mutations to Small Molecule Sensitivity in Non-Small-Cell Lung Cancer

Relating Activating K-Ras Mutations to Small Molecule Sensitivity in Non-Small-Cell Lung Cancer. Flavian D. Brown Carleton College Class of 2009. Lung Cancer. Leading cause of death from cancer in the world Over 90% of NSCLC contain mutations in EGFR, BRAF and K-Ras Discovery of Gefitnib.

336 views • 15 slides

NON-SMALL CELL LUNG CANCER 2006 RADIOTHERAPY

NON-SMALL CELL LUNG CANCER 2006 RADIOTHERAPY. Prof Dr Serdar ÖZKÖK Ege University Medical School Department of Radiation Oncology. Stage I-II NSCLC. Postoperative RT Curative RT. PORT Meta-analysis (PORT Meta-analysis Trialist Group; Lancet 1998; 352;9124: 257).

950 views • 71 slides

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib. N Engl J Med. 2011 Mar 10;364(10):947-55. Presentor: CR 周益聖 Supervisor: Vs 顏厥全. 財團法人台灣癌症臨床研究發展基金會. Outline. Introduction of lung cancer EGFR in NSCLC Important clinical trials of TKI

1.29k views • 49 slides

First-Line Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

First-Line Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Thoracic Tumors. Lung Cancer Globally, 1.4 million new cases each year 1 The leading cause of cancer death worldwide 1 Approximately 80% of lung cancer cases are NSCLC 2 NSCLC

970 views • 39 slides

Non Small Cell Lung Cancer Histopathology

Non Small Cell Lung Cancer Histopathology. ד"ר יהודית זנדבנק 26.06.09. Lecture outlines. WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes – SCC, AdCa, LCLC Histology / Cytology IHC DD

857 views • 67 slides

Development of an EGFR/KRAS testing service for Non-Small Cell Lung Cancer (NSCLC)

Development of an EGFR/KRAS testing service for Non-Small Cell Lung Cancer (NSCLC). Joel Tracey 1 , Caroline Clark 1 , Christine Bell 1 , Keith Kerr 2 , Marianne Nicholson 3 , Aileen Osborne 1 , Zosia Miedzybrodzka 1 , Kevin Kelly 1

587 views • 24 slides

Utilizing Molecular Prognosis in Early-Stage Non-Small Cell Lung Cancer

Utilizing Molecular Prognosis in Early-Stage Non-Small Cell Lung Cancer. Title Slide. Disclosure. Life Technologies Corporation (Consultant). Molecular Prognosis in Early-Stage Non-Small Cell Lung Cancer. Objectives Need for better prognostic information in managing early stage NSCLC

518 views • 25 slides

Treatment of Unresectable Advanced Non–Small Cell Lung Cancer (NSCLC)

Treatment of Unresectable Advanced Non–Small Cell Lung Cancer (NSCLC). ASCO 2007: Treatment of Unresectable Advanced Non–Small Cell Lung Cancer (NSCLC). Bevacizumab improves progression-free survival in advanced NSCLC

646 views • 48 slides

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer. Signs and symptoms. persistent cough trouble breathing chest discomfort wheezing streaks of blood in sputum hoarseness loss of appetite weight loss for no known reason feeling very tired. Diagnostic tests. chest X-rays CT, PET scan sputum cytology

1.24k views • 67 slides

Treatment in Advanced Non-Small Cell Lung Cancer

Treatment in Advanced Non-Small Cell Lung Cancer. NSCLC| Epidemiology- Australia. 5 th most commonly diagnosed cancer in Australia 8.9% of new cancer diagnoses In 2009: 10,193 cases ( 6034 men, 4159 women) Projection to 2020  13,640 Mortality

839 views • 49 slides

Redefining Non-small Cell Lung Cancer: The Role of Histology

Redefining Non-small Cell Lung Cancer: The Role of Histology. History of Therapy in Advanced NSCLC: FDA Approval Dates. ECOG 1594: What Did It Teach Us?. Bevacizumab in NSCLC: Key Clinical Outcomes. Grade 3-5 Non-hematologic Toxicity Associated With Bevacizumab. AVAIL Study Design.

452 views • 16 slides

NON SMALL CELL LUNG CANCER

NON SMALL CELL LUNG CANCER. Recent CT evolutions of Non Small Cell Lung Cancer. Arrival of new oral formulations Development of multimodal treatments Development of chemotherapy for early stages. Role of chemotherapy in Non Small Cell Lung Cancer. STAGE III:

406 views • 11 slides

Efficacy, safety and economy of icotinib for advanced non-small cell lung cancer: a meta-analysis

To evaluate the efficacy and safety of Icotinib in the treatment of advanced Non-small Cell Lung Cancer (NSCLC).

122 views • 10 slides

Meta-Analysis of P73 Polymorphism and Risk of Non-Small Cell Lung Cancer

Non-small lung cancer (NSCLC) was a subtype for lung cancer, one of the most common malignancies of the world, especially in male. The incidence of NSCLC is largely affected by tobacco smoking.

86 views • 7 slides

SMALL CELL LUNG CANCER (SCLC) and TKIs in NSCLC

SMALL CELL LUNG CANCER (SCLC) and TKIs in NSCLC. G. Giaccone Chief Medical Oncology Branch National Cancer Institute Bethesda, Maryland. U.S. Cancer Mortality: Men. CA Cancer J Clin 2006. U.S. Cancer Mortality: Women. CA Cancer J Clin 2006. Worldwide Prevalence of Lung Cancer.

755 views • 73 slides

More Related